Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joaquim Bellmunt

Showing results (1-10 of 438) with videos related to

Pageof 44
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
What are the expected developments in the medical treatment of bladder cancerJoaquim Bellmunt
Biomedicines|August 4, 2018
Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4Joaquim Bellmunt
Lancet (London, England)|September 17, 2017
Antiangiogenesis to curb urothelial cancerJoaquim Bellmunt
European Urology|September 10, 2008
Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail?Joaquim Bellmunt
European Urology|October 16, 2012
Tackling the bone with alpha emitters in metastatic castration-resistant prostate cancer patientsJoaquim Bellmunt
Hematology/Oncology Clinics of North America|April 4, 2015
Bladder cancerJoaquim Bellmunt
The Lancet. Oncology|June 4, 2021
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma - Author's replyJoaquim Bellmunt
European Urology|October 27, 2015
Docetaxel for Castration-sensitive Prostate Cancer: Wrapping up Unfinished Business?Guru Sonpavde, Joaquim Bellmunt
Future Oncology (London, England)|February 4, 2016
The evolving role of enzalutamide on the treatment of prostate cancerRosa Nadal, Joaquim Bellmunt
Nature Reviews. Urology|April 14, 2016
Bladder cancer: Angiogenesis as a therapeutic target in urothelial carcinomaGuru Sonpavde, Joaquim Bellmunt
Pageof 44

Showing results (1-10 of 438) with videos related to

Sort By:
Pageof 44
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
What are the expected developments in the medical treatment of bladder cancerJoaquim Bellmunt
Biomedicines|August 4, 2018
Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4Joaquim Bellmunt
Lancet (London, England)|September 17, 2017
Antiangiogenesis to curb urothelial cancerJoaquim Bellmunt
European Urology|September 10, 2008
Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail?Joaquim Bellmunt
European Urology|October 16, 2012
Tackling the bone with alpha emitters in metastatic castration-resistant prostate cancer patientsJoaquim Bellmunt
Hematology/Oncology Clinics of North America|April 4, 2015
Bladder cancerJoaquim Bellmunt
The Lancet. Oncology|June 4, 2021
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma - Author's replyJoaquim Bellmunt
European Urology|October 27, 2015
Docetaxel for Castration-sensitive Prostate Cancer: Wrapping up Unfinished Business?Guru Sonpavde, Joaquim Bellmunt
Future Oncology (London, England)|February 4, 2016
The evolving role of enzalutamide on the treatment of prostate cancerRosa Nadal, Joaquim Bellmunt
Nature Reviews. Urology|April 14, 2016
Bladder cancer: Angiogenesis as a therapeutic target in urothelial carcinomaGuru Sonpavde, Joaquim Bellmunt
Pageof 44